SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (77)12/5/1997 6:12:00 PM
From: Pseudo Biologist  Read Replies (1) | Respond to of 666
 
Rick, I will email you later. You/we should thank V1 twice as he was the "evangelist" on this one for sure. Someone I know may have attended the ASH talk; I'll try to get further details if that was indeed the case.

I think I've seen the 50:50 GNE/IDPH number before, but Merril's Hecht wrote 30-40% of U.S. *profits* in a September report.

PB



To: scaram(o)uche who wrote (77)12/6/1997 12:23:00 PM
From: Peter Singleton  Respond to of 666
 
Rick,

IDPH IR (Connie Matsui) told me in early November that the IDPH/GNE rituxan royalty is not public information, but the guidance they are giving analysts is that it's generous, less than 50%, and on a increasing, sliding scale based on sales.

Who knows, maybe starting at 30% increasing to 40%?

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News